AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Point-of-Care Diagnostics Market Expected to Grow with a CAGR of 7.3% During the Forecast Period, 2019-2025 - ResearchAndMarkets.com

October 11, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Oct 11, 2019--

The “Point-of-Care Diagnostics Market By Products, Prescription Mode, End-users, and Regions: Global Forecast up to 2025” report has been added to ResearchAndMarkets.com’s offering.

Overview of the Global Point-of-Care Diagnostics Market Research:

The author’s market research report predicts that the global point-of-care diagnostics market will grow at a CAGR of 7.3% during the forecast period 2019-2025.

The market has witnessed steady growth in the past few years, and the advancements in technology with the launch of innovative products have increased the adoption of point-of-care diagnostics products. The market is fueled by the increasing prevalence of infectious diseases, upsurge in the incidence of lifestyle diseases, increasing geriatric population, and rising adoption of the technology in emerging countries.

According to the author analysis, North America accounted for the largest share of the global point-of-care diagnostics market in 2018, and Asia Pacific is expected to grow at a high CAGR during the forecast period. According to a report released by the Centers for Disease Control and Prevention (CDC), in the US alone, more than 100 million adults are now living with diabetes or prediabetes. According to an estimation, in the US, approximately 1,688,780 new cancer cases were diagnosed and 600,920 cancer deaths were reported in 2017. Canada had an estimated 206,200 new cases of cancer and 80,800 deaths from cancer in 2017. Cardiovascular disease (CVD) accounts for approximately 800,000 deaths in the US, and on an average, one person dies from CVD every 40 seconds in the US. Coronary heart disease accounts for the majority of CVD deaths followed by stroke and heart failure. The presence of dominant players in the region, promising reimbursement facilities, availability of hi-tech medical technologies, and growing patient base for lifestyle diseases make North America the dominant shareholder in the market.

Global Point-of-Care Diagnostics Market Research Competitive Analysis: The market is growing at a steady rate with a CAGR of 7.3% during the forecast period 2019-2025. A lot of new players are concentrating on this market to deliver advanced and innovative products. The increasing adoption of point-of-care diagnostics has resulted in increased approvals, new launches, strategic collaborations, acquisitions, and increased funding. For instance, in February 2019, HemoCue received the FDA approval for its HemoCue Hb 801 System that quantitatively measures hemoglobin in capillary or venous whole blood. In June 2019, Abbott launched its Afinion HbA1c Dx assay available for use on the Afinion 2 Analyzer, as well as the Afinion AS100 Analyzer. Afinion HbA1c Dx assay is the first rapid point-of-care test approved by the FDA to aid healthcare professionals in the diagnosis of diabetes. In March 2019, Group K Diagnostics partnered with the US Centers for Disease Control and Prevention to design and evaluate a prototype reverse transcriptase loop-mediated isothermal amplification assay to detect Zika virus RNA at POC.

Key Competitive Facts:

Key Takeaways:

Key Topics Covered:

1 Industry Outlook

1.1 Industry Overview

1.2 Total Addressable Market

1.3 Industry Trends

2 Report Outline

2.1 Report Scope

2.2 Report Summary

2.3 Research Methodology

2.4 Report Assumptions

3 Market Snapshot

3.1 Market Definition - Infoholic Research

3.2 Advantages of Point-of-Care Testing

3.3 Disadvantages of Point-of-Care Testing

3.4 Segmented Addressable Market

3.5 Trends in the Point-of-Care Diagnostics Market

3.6 Related Markets

3.6.1 Molecular Diagnostics

3.6.2 Infectious Disease Diagnostics

4 Market Outlook

4.1 Market Segmentation

4.2 PEST Analysis

4.3 Porter 5 (Five) Forces

5 Market Characteristics

5.1 DRO - Market Dynamics

5.1.1 Drivers

5.1.1.1 Increasing prevalence of infectious disease

5.1.1.2 Growing incidence of lifestyle disease

5.1.1.3 Technological innovations

5.1.1.4 Increasing adoption of point-of-care diagnostics

5.1.2 Opportunities

5.1.2.1 Growth opportunities in emerging markets

5.1.2.2 Increasing awareness towards point-of-care diagnostics in developing countries

5.1.3 Restraints

5.1.3.1 Stringent approval process

5.1.3.2 Product recalls

5.1.3.3 Unfavorable reimbursement scenario

5.2 DRO - Impact Analysis

5.3 Key Stakeholders

6 Product: Market Size and Analysis

6.1 Overview

6.2 Glucose Monitoring

6.3 Infectious Disease Testing

6.3.1 Influenza Testing

6.3.2 HIV Testing

6.3.3 Hepatitis Testing

6.3.4 Tuberculosis Testing

6.3.5 Sexually Transmitted Diseases Testing

6.3.6 Healthcare-associated Infections Testing

6.3.7 Respiratory Infections Testing

6.3.8 Others

6.4 Pregnancy and Fertility Testing

6.5 Hematology Testing

6.6 Cardiometabolic Monitoring

6.7 Urinalysis Testing

6.8 Coagulation Monitoring

6.9 Tumor or Cancer Marker Testing

6.10 Cholesterol Testing

6.11 Drugs of Abuse Testing

6.12 Others

7 Prescription Mode: Market Size and Analysis

7.1 Overview

7.2 Prescription-based Point-of-Care Diagnostics

7.3 Over the Counter-based Point-of-Care Diagnostics

8 End-users: Market Size and Analysis

8.1 Overview

8.2 Hospitals

8.3 Clinics/Physician Office Laboratory (POL)

8.4 Home Care

8.5 Ambulatory Care

8.6 Others

9 Regions: Market Size and Analysis

9.1 Overview

9.2 North America

9.2.2 US

9.2.3 Canada

9.3 Europe

9.3.2 UK

9.3.3 Germany

9.3.4 France

9.3.5 Spain

9.3.6 Italy

9.3.7 Others

9.4 APAC

9.4.2 India

9.4.3 China

9.5 Rest of the World

10 Competitive Landscape

10.1 Overview

11 Vendors Profile

11.1 Abbott Laboratories

11.1.1 Overview

11.1.2 Business Units

11.1.3 Geographic Revenue

11.1.4 Business Focus

11.1.5 SWOT Analysis

11.1.6 Business Strategies

11.2 F. Hoffmann-La Roche Ltd.

11.3 Johnson & Johnson

11.4 Danaher Corporation

11.5 Siemens Healthineers Inc. (Siemens AG)

12 Companies to Watch For

12.1 Trinity Biotech plc

12.1.1 Overview

12.2 Qiagen N.V.

12.3 BioMerieux S.A.

12.4 OraSure Technologies Inc.

12.5 Instrumentation Laboratory (A Werfen Company)

12.6 Becton Dickinson and Company

12.7 Nova Biomedical

For more information about this report visit https://www.researchandmarkets.com/r/enjo6x

View source version on businesswire.com:https://www.businesswire.com/news/home/20191011005173/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH GENERAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 10/11/2019 05:17 AM/DISC: 10/11/2019 05:17 AM

http://www.businesswire.com/news/home/20191011005173/en